Roberts Zachary 4

What Happened Zachary Roberts, EVP of Research & Development at Allogene Therapeutics (ALLO), received two awards on 2026-02-02 totaling 922,070 derivative shares (718,763 + 203,307) reported at $0.00 (awards/derivative acquisitions). On the same date he sold 35,700 common shares in an open-market/private sale at a weighted average price of $1.77 (range $1.71–$1.87), generating approximately $63,189. The sale was a mandatory "sell-to-cover" to satisfy tax withholding obligations tied to the vesting awards, not a discretionary trade.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (appears timely — within standard 2 business days).
• Sale: 35,700 shares sold; weighted avg price reported $1.77; price range $1.71–$1.87; proceeds ≈ $63,189. (Footnote F2: weighted average; detailed breakdown available on request.)
• Awards: 718,763 and 203,307 derivative shares granted (total 922,070) reported at $0.00 (Footnote F4 identifies RSUs).
• Vesting: Footnote F4 — RSUs vest in four equal annual installments starting Feb 2, 2026 (subject to continued service). Footnote F3 describes a 25%/then-monthly vesting schedule (25% on Feb 2, 2027, remainder in 36 monthly installments) for the other award-type referenced in the filing.
• Sale reason: Footnote F1 — sale was mandated by the company's "sell to cover" election to satisfy tax withholding; not a discretionary sale by the insider.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.

Context

• RSUs/awards are compensation and represent a contingent right to receive shares upon vesting; they are not an immediate market buy signal. The simultaneous mandatory sell-to-cover is common when RSUs vest and does not necessarily indicate the insider’s view on the stock.
• Derivative entries here reflect awards (not an open-market purchase). Retail investors should treat grants as compensation actions and note vesting schedules before assuming future share supply or insider conviction.